Literature DB >> 11870200

Medical management of Parkinson's disease.

C E Clarke1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11870200      PMCID： PMC1765581          DOI： 10.1136/jnnp.72.suppl_1.i22

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  7 in total

1.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

Authors:  O Rascol; D J Brooks; A D Korczyn; P P De Deyn; C E Clarke; A E Lang
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

Review 2.  An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.

Authors:  C W Olanow; R L Watts; W C Koller
Journal:  Neurology       Date:  2001-06       Impact factor: 9.910

3.  Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.

Authors:  Y Ben-Shlomo; A Churchyard; J Head; B Hurwitz; P Overstall; J Ockelford; A J Lees
Journal:  BMJ       Date:  1998-04-18

Review 4.  Science, medicine, and the future: Parkinson's disease.

Authors:  A H Schapira
Journal:  BMJ       Date:  1999-01-30

5.  Subcutaneous apomorphine in the treatment of Parkinson's disease.

Authors:  J P Frankel; A J Lees; P A Kempster; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

6.  Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group.

Authors:  K Bhatia; D J Brooks; D J Burn; C E Clarke; J Playfer; G V Sawle; A H Schapira; D Stewart; A C Williams
Journal:  Hosp Med       Date:  1998-06

Review 7.  Does levodopa therapy delay death in Parkinson's disease? A review of the evidence.

Authors:  C E Clarke
Journal:  Mov Disord       Date:  1995-05       Impact factor: 10.338
  7 in total
  12 in total

Review 1.  Evaluating drug treatments for Parkinson's disease: how good are the trials?

Authors:  Keith Wheatley; Rebecca L Stowe; Carl E Clarke; Robert K Hills; Adrian C Williams; Richard Gray
Journal:  BMJ       Date:  2002-06-22

2.  M1 muscarinic receptors contribute to, whereas M4 receptors inhibit, dopamine D1 receptor-induced [3H]-cyclic AMP accumulation in rat striatal slices.

Authors:  Enrique Sánchez-Lemus; José-Antonio Arias-Montaño
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

3.  Dopamine Deficiency Reduces Striatal Cholinergic Interneuron Function in Models of Parkinson's Disease.

Authors:  Jonathan W McKinley; Ziqing Shi; Ivana Kawikova; Matthew Hur; Ian J Bamford; Suma Priya Sudarsana Devi; Annie Vahedipour; Martin Darvas; Nigel S Bamford
Journal:  Neuron       Date:  2019-07-16       Impact factor: 17.173

4.  Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.

Authors:  Thomas Müller; Birgit Voss; Kerstin Hellwig; Franz Josef Stein; Thorsten Schulte; Horst Przuntek
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 5.  The cholinergic system and Parkinson disease.

Authors:  Nicolaas I Bohnen; Roger L Albin
Journal:  Behav Brain Res       Date:  2010-01-07       Impact factor: 3.332

6.  Medical management of Parkinson's disease: focus on neuroprotection.

Authors:  Marie-Catherine Boll; Mireya Alcaraz-Zubeldia; Camilo Rios
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

7.  A Comparative Pharmacokinetics Study of the Anti-Parkinsonian Drug Pramipexole.

Authors:  Ratih S I Putri; Effi Setiawati; Syifa A Aziswan; Fenny Ong; Raymond R Tjandrawinata; Liana W Susanto
Journal:  Sci Pharm       Date:  2016-11-18

8.  Botulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson's Disease Differently Affects Behavior.

Authors:  Veronica A Antipova; Carsten Holzmann; Oliver Schmitt; Andreas Wree; Alexander Hawlitschka
Journal:  Front Behav Neurosci       Date:  2017-06-21       Impact factor: 3.558

Review 9.  Experimental Intrastriatal Applications of Botulinum Neurotoxin-A: A Review.

Authors:  Alexander Hawlitschka; Andreas Wree
Journal:  Int J Mol Sci       Date:  2018-05-07       Impact factor: 5.923

10.  Potential cellular and regenerative approaches for the treatment of Parkinson's disease.

Authors:  Emma L Lane; Olivia J Handley; Anne E Rosser; Stephen B Dunnett
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.